Acorda said the acquisition would expand its pipeline in Parkinson’s disease therapies.
The company will offer 0.294 euros for each Biotie share, a premium of about 95 percent compared with the closing price on Monday.
Biotie shares had jumped 79 percent to 0.27 euros by 0824 GMT (3.24 a.m. ET).
Reporting by Tuomas Forsell; Editing by Jussi Rosendahl and Mark Potter
Our Standards: The Thomson Reuters Trust Principles.